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Common functional polymorphisms in the methylenetetrahydrofolate reductase (MTHFR)
gene, a key enzyme in folate and homocysteine metabolism, influence risk for a variety of
complex disorders, including developmental, vascular, and neurological diseases. MTHFR
deficiency is associated with elevation of homocysteine levels and alterations in the
methylation cycle. Here, using young and aged Mthfr knockout mouse models, we
show that mild MTHFR deficiency can lead to brain-region specific impairment of the
methylation of Ser/Thr protein phosphatase 2A (PP2A). Relative to wild-type controls,
decreased expression levels of PP2A and leucine carboxyl methyltransferase (LCMT1)
were primarily observed in the hippocampus and cerebellum, and to a lesser extent in
the cortex of young null Mthfr−/− and aged heterozygous Mthfr+/− mice. A marked down
regulation of LCMT1 correlated with the loss of PP2A/Bα holoenzymes. Dietary folate
deficiency significantly decreased LCMT1, methylated PP2A and PP2A/Bα levels in all brain
regions examined from aged Mthfr+/+ mice, and further exacerbated the regional effects
of MTHFR deficiency in aged Mthfr+/− mice. In turn, the down regulation of PP2A/Bα
was associated with enhanced phosphorylation of Tau, a neuropathological hallmark
of Alzheimer’s disease (AD). Our findings identify hypomethylation of PP2A enzymes,
which are major CNS phosphatases, as a novel mechanism by which MTHFR deficiency
and Mthfr gene-diet interactions could lead to disruption of neuronal homeostasis, and
increase the risk for a variety of neuropsychiatric disorders, including age-related diseases
like sporadic AD.
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INTRODUCTION
5,10-methylenetetrahydrofolate reductase (MTHFR) is the rate-
limiting enzyme for converting folate to its active form,
methylfolate (5-MTHF). 5-MTHF is a necessary co-factor for
remethylation of homocysteine to methionine, which is essen-
tial for production of S-adenosylmethionine (SAM), the univer-
sal methyl donor (Figure 1). Severe MTHFR deficiency is the
most common inborn error of folate metabolism, and leads to
decreased red cell folate levels, elevated plasma total homocys-
teine (tHcy) levels, homocysteinuria, hypomethioninemia, and
impaired cellular methylation potential (Goyette et al., 1996).
It is associated with variable clinical outcomes, ranging from
early neonatal demise to later-onset damage to the nervous
and vascular systems, resulting in varying degrees of develop-
mental delay, neurological impairment, motor dysfunction, gait
abnormalities, seizures, and thrombotic events. Notably, there
is a relatively high prevalence of functional genetic Mthfr poly-
morphisms in the general population (Botto and Yang, 2000).
Among them, the common human Mthfr 677C→T gene poly-
morphism is associated with mild MTHFR deficiency, and is
the most frequent cause of hyperhomocysteinemia (Leclerc and
Rozen, 2007). In vitro, the C to T change at nucleotide posi-
tion 677 leads to production of thermolabile MTHFR enzymes
with ∼35% and ∼65% decreased MTHFR activity in het-
erozygous 677CT and homozygous 677TT individuals, respec-
tively (Rozen, 1997). Of particular relevance to the CNS, the
Mthfr 677CT polymorphism has been clinically identified as
a risk factor for development neural tube defects (Botto and
Yang, 2000), vascular disease and stroke (McNulty et al., 2012),
and a variety of neuropsychiatric diseases, including Down
syndrome (Hobbs et al., 2000), epilepsy (Wu et al., 2014),
migraine (Liu et al., 2014), depression, schizophrenia and bipo-
lar disorder (Gilbody et al., 2007). Homozygosity for Mthfr
677TT is also associated in selected populations with age-
related neurodegenerative diseases such as Alzheimer’s disease
(AD; Kageyama et al., 2008; Wang et al., 2008; Hua et al.,
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FIGURE 1 | Model of the link between MTHFR, folate, PP2A
methylation and Tau phosphorylation. 5-MTHF, produced via the
action of MTHFR, is essential for remethylation of homocysteine (Hcy)
to methionine, the precursor of S-adenosylmethionine (SAM), the
universal methyl donor. Methylation of PP2A catalytic subunit on
Leu-309 by the dedicated SAM-dependent LCMT1 methyltransferase
promotes the biogenesis of PP2A/Bα heterotrimers, the primary Tau
Ser/Thr phosphatases in the brain. Common C677→T polymorphisms in
the mthfr gene induce mild MTHFR deficiency, leading to reduced
5-MTHF levels. Folate deficiency promotes accumulation of Hcy, which
may be converted back to SAH, a potent inhibitor of LCMT1 activity.
MAT, methionine adenosine transferase; MS, methionine synthase;
MTHF, methyltetrahydrofolate; SAHH, SAH hydrolase; THF,
tetrahydrofolate.
2011; Coppede et al., 2012) and Parkinson’s disease (Wu et al.,
2013).
Despite numerous clinical studies, the effects of MTHFR
deficiency at the molecular level are not well understood.
By affecting folate and homocysteine metabolism, MTHFR
polymorphisms have the potential to disrupt the transfer
of one-carbon units, thereby influencing many methylation-
sensitive targets (Figure 1). We hypothesized that one of
them might be protein phosphatase 2A (PP2A), a large fam-
ily of essential Ser/Thr protein phosphatases (Sontag and
Sontag, 2014). Significantly, PP2A is regulated by Leucine
carboxyl methyltransferase 1 (LCMT1)-dependent methyla-
tion of its catalytic C subunit (PP2Ac), which influences
PP2A holoenzyme biogenesis and substrate specificity (De
Baere et al., 1999; Leulliot et al., 2004; Stanevich et al.,
2011; Tsai et al., 2011). We have reported in vivo that
low folate status (Sontag et al., 2008) and hyperhomocys-
teinemia (Sontag et al., 2007), lead to down regulation of
expression levels of LCMT1, PP2A methylation, and PP2A
holoenzymes containing the regulatory Bα (or PPP2R2A) sub-
unit (PP2A/Bα). This correlates with increased phosphory-
lation of specific PP2A/Bα substrates, such as Tau proteins
(Sontag and Sontag, 2014). The accumulation of phosphory-
lated Tau (p-Tau) species, a neuropathological hallmark of AD
and other tauopathies, mediates neurotoxicity in AD mouse
models (Wang et al., 2013). Here, using young and aged Mthfr
knockout mouse models, we investigated whether MTHFR defi-
ciency and Mthfr-low folate gene-diet interactions can poten-
tially affect the methylation state of PP2A, and its substrate,
Tau.
MATERIALS AND METHODS
MATERIALS
Unless indicated, all chemicals used in this study were
obtained from Sigma-Aldrich (St. Louis, MO and Castle Hill,
Australia).
Mthfr MICE AND FOLATE DEFICIENCY
All experiments with mice were performed in accordance
with protocols approved by the Institutional Animal Care and
Use Committee at Baylor Research Institute. Wild-type (Wt)
Mthfr+/+, heterozygous (het) Mthfr+/− and homozygous (null)
Mthfr−/− knockout mice in the C57Bl/6 background (Chen
et al., 2001) were obtained from Dr. Rima Rozen (The Research
Institute of the McGill University Health Center, Montreal,
Quebec, Canada). Mice were bred, genotyped and housed in
cages with a maximum of 4 mice per cage, maintained in a
temperature-controlled animal facility on a 12-h light dark cycle,
and were allowed access to food and water ad libitum. At ∼5
weeks of age, a subset of mice (n = 10 female per genotype)
fed a normal chow diet was sacrificed by CO2 asphyxiation.
At ∼16 months of age, subsets of wt mice were placed for
6 months on an amino acid defined diet (n = 10 female per
group) with either a normal folate (6.7 mg/kg, NF) or low
folate (0.2 mg/kg, LF) content. These custom diets (Harland
Teklad) also contained succinylsulfathiazole (10 g/kg) to inhibit
gastrointestinal bacterial growth and prevent absorption of folate
from this source (Sontag et al., 2008). The diets did not induce
any statistically significant changes in mouse weight in any of
the group studied (mean weight in grams ± SD: Wt mice
on NF diet, 37 ± 9 at baseline, 40 ± 7 at 22 months; het
mice on NF diet, 43 ± 7 at baseline, 41 ± 6 at 22 months;
wt mice on LF diet, 35 ± 7 g at baseline, 34 ± 3 g at 22
months; het mice on LF diet, 46 ± 14 g at baseline, 40 ±
10 g at 22 months). At ∼22 months of age, mice were sac-
rificed by CO2 asphyxiation. Blood was obtained by cardiac
puncture and brain tissue rapidly removed for regional dissection
(Sontag et al., 2008). Tissues were stored at −80◦C until time of
analysis.
PLASMAMETABOLITE ANALYSIS
Plasma tHcy was determined by high pressure liquid chromatog-
raphy with fluorescence detection (Ubbink et al., 1991). Plasma
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5-MTHF was measured by liquid chromatography mass spec-
trometry as previously described (Nelson et al., 2004).
DETERMINATION OF PROTEIN EXPRESSION AND PP2A METHYLATION
LEVELS
Total brain homogenates (0.1 g tissue/ml of buffer) were prepared
from each brain region exactly as described previously (Sontag
et al., 2007, 2008). Aliquots were analyzed immediately for PP2A
methylation or kept frozen at −80◦C for future analyses. Equiv-
alent aliquots (5 µl) of brain homogenates were resolved on 4–
12% Bis-Tris gels using the NU-PAGE system (Thermo Fisher
Scientific) followed by quantitative Western blotting. Precision
Plus ProteinTM Standards (BIO-RAD) were used as molecular
weight standards. Antibodies against LCMT1 (clone 4A4, Merck
Millipore #05-592), Bα (clone 2G9, Merck Millipore #05-849),
total Tau (rabbit anti-Tau T-1308-1, rPeptide) and Tau phospho-
rylated at the PHF-1 epitope (Greenberg et al., 1992) were used
to assess protein expression levels exactly as described previously
(Sontag et al., 2007, 2008; Bottiglieri et al., 2012). Methylation
of PP2A was determined using two methods. First, western
blots of brain tissue samples were probed with monoclonal anti-
methyl specific PP2A antibodies (clone 2A10, Merck Millipore
#04-1479), followed by re-probing with methylation-insensitive
antibodies (clone 46, BD Biosciences #610556) (Sontag et al.,
2007). In the second method, equivalent aliquots of brain tissue
homogenates were incubated for 30 min at 37◦C in the absence
or presence of 0.2 N sodium hydroxide (NaOH). Alkaline treat-
ment results in complete demethylation of PP2Ac at Leu-309.
NaOH-treated and untreated samples were then analyzed by NU-
PAGE electrophoresis followed by Western blotting with mon-
oclonal anti-demethylated PP2Ac antibodies (clone 1D6, Merck
Millipore #05-421) to detect demethylated (NaOH-untreated
samples) and total PP2Ac (NaOH-treated samples) (Bottiglieri
et al., 2012). All the blots were re-blotted with monoclonal anti-
actin antibodies (clone 4, MAB1501 Merck Millipore) to allow
normalization for protein loading. Western blotting was per-
formed using Infrared IRDye®-labeled secondary antibodies and
the Odyssey™ Infrared imaging system (LI-COR Biosciences).
Band intensity was determined using the associated Image Studio
Lite version 3.1 Software (LI-COR Biosciences) to accurately
quantify protein levels. Some samples were also analyzed in
duplicate by Western blotting using chemiluminescence detec-
tion system (Pierce), followed by densitometry (Sontag et al.,
2007).
STATISTICS
Data were analyzed using one-way ANOVA with post hoc Tukey’s
multiple comparison test. Differences with p-values < 0.05 were
considered statistically significant.
RESULTS
MTHFR DEFICIENCY IN YOUNG MICE IMPAIRS BRAIN LCMT1 PROTEIN
EXPRESSION AND PP2A METHYLATION IN A REGION-SPECIFIC
MANNER
To investigate whether MTHFR deficiency can influence the
methylation of PP2A and its substrate Tau, we first analyzed
young murine models of mild (Mthfr+/−) and severe (Mthfr−/−)
MTHFR deficiency. These well-characterized knockout mice have
been shown to reproduce the biochemical and clinical conse-
quences of Mthfr 677C→T polymorphisms in human (Chen
et al., 2001; Ghandour et al., 2004). Relative to their 5-week-old
wt littermates, there was an average ∼1.6-fold increase in plasma
tHcy levels in het mthfr+/− mice, while null Mthfr−/− mice
exhibited a ∼10-fold increase in plasma tHcy levels (Figure 2),
in agreement with earlier studies (Chen et al., 2001). It is well
established that impairment of MTHFR activity can lead to
reduced 5-MTHF levels and elevated tHcy levels that compromise
SAM-dependent methylation reactions (Chen et al., 2001). Signif-
icantly, the activity of LCMT1, the sole PP2A methyltransferase
(MacKay et al., 2013), is dependent on SAM supply (Lee et al.,
1996; Leulliot et al., 2004; Sontag et al., 2007; Tsai et al., 2011).
Accordingly, we found that, relative to wt mice, methylation of
PP2Ac was reduced in all the brain regions examined from het
or null mthfr knockouts (Figure 3A). Of note, the extent of
decrease in methylated PP2Ac levels was variable among regions,
being highest in the hippocampus, and lowest in the striatum. We
have previously reported that, besides affecting SAM-dependent
LCMT1 methyltransferase activity, in vivo alterations in plasma
folate and/or tHcy levels can also result in down regulation of
brain LCMT1 at the protein level, through a yet unresolved
mechanism (Sontag et al., 2007, 2008; Bottiglieri et al., 2012).
Interestingly, a marked decrease in LCMT1 expression levels was
observed in the hippocampus and cerebellum, and to a lesser
extent in the cortex, but not in the midbrain and striatum from
young het Mthfr+/− mice, relative to wt mice (Figures 3B,C).
Compared to their wt littermates, lower LCMT1 protein amounts
were observed in all brain regions of null Mthfr−/− mice, with
the exception of the striatum. Notably, the down-regulation of
LCMT1 expression was most prevalent in the hippocampus,
wherein the loss of methylated PP2Ac was maximal (Figure 3A),
FIGURE 2 | Plasma tHcy levels in Mthfr knockout mice. Plasma tHcy
levels were measured in 5-week-old wt mthfr+/+, het mthfr+/− and null
mthfr−/− mice (n = 10 mice/ group).
Frontiers in Aging Neuroscience www.frontiersin.org August 2014 | Volume 6 | Article 214 | 3
Sontag et al. MTHFR deficiency, PP2A methylation and Tau
FIGURE 3 | Alterations in regional brain levels of methylated PP2Ac
and LCMT1 in young mice models of mild and severe MTHFR
deficiency. Regional brain homogenates from 5-week-old wt mthfr+/+
(black bars), het mthfr+/− (gray bars), and null mthfr−/− (white bars) mice
were analyzed by quantitative Western blotting for relative protein
expression levels of methylated PP2Ac (A) and LCMT1 (B,C). Values
represent mean ± SD for 6 mice per group; * p < 0.05, het or null
compared to wt mice; # p < 0.05, null vs. het mice. Representative LCMT1
blots of two brain regions are shown in (B).
in line with the observation that knock down of LCMT1 results
in a significant reduction in PP2Ac methylation (Lee and Pallas,
2007; Sontag et al., 2008; MacKay et al., 2013). Together, these
results suggest that MTHFR deficiency affect LCMT1 and PP2A
methylation in a brain region-specific manner.
SEVERE MTHFR DEFICIENCY IN YOUNG MICE INDUCES A DOWN
REGULATION OF PP2A/Bα AND CONCOMITANT ENHANCEMENT OF
p-Tau LEVELS IN THE HIPPOCAMPUS AND CEREBELLUM, AND TO A
LESSER EXTENT, IN THE CORTEX
We and others have shown that, by reducing the forma-
tion of PP2A/Bα heterotrimers, down regulation of LCMT1 is
FIGURE 4 | Regional alterations in PP2A/Bα and p-Tau levels in young
mice models of mild and severe MTHFR deficiency. Regional brain
homogenates from the same mice described in Figure 3 were
comparatively analyzed by quantitative Western blotting for expression
levels of PP2A/Bα (A,B) and Tau phosphorylated at the PHF-1 epitope (C,D).
Bar shading and symbols as in Figure 3. Representative blots of two
regions are shown in (A) and (C).
accompanied with a preferential loss of endogenous PP2A/Bα
isoforms (Lee and Pallas, 2007; Sontag et al., 2008). Likewise, the
region-specific decrease in LCMT1 expression levels (Figure 3C)
correlated with a similar reduction in PP2A/Bα expression lev-
els (Figures 4A,B) in het and null Mthfr mice. As observed
with LCMT1, the down regulation of PP2A/Bα expression levels
was more prevalent in the hippocampal and cerebellar regions.
Since the PP2A/Bα heterotrimer is a major Tau phosphatase
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(Sontag et al., 1996; Xu et al., 2008), we next investigated
whether the reduction in PP2A/Bα amounts correlated with
enhanced phosphorylation of endogenous Tau at the AD-like
p-Ser396/Ser404 PHF-1 epitope. Levels of p-Tau (PHF-1) in
each brain region were similar in wt and het MTHFR mice
(Figures 4C,D). However, relative to control wt mice, a ∼30–
50% enhancement of Tau phosphorylation was observed in the
hippocampus and cerebellum of null mice, the only regions
wherein PP2A/Bα levels were markedly decreased (Figure 4B).
A minor increase in p-Tau levels, which correlated with a
smaller loss of PP2A/Bα (Figure 4B) was also observed in cor-
tical homogenates of null mice. In contrast, relative to con-
trols, there was no change in p-Tau or PP2A/Bα amounts
measured in the midbrain and striatum. Together, these data
point to an inverse relationship between PP2A/Bα and p-Tau
levels. They also suggest that a certain threshold of LCMT1
and PP2A/Bα down regulation, which selectively occurs in the
hippocampal, cerebellar and cortical regions of young null
mice, is required to achieve a significant increase in Tau
phosphorylation.
AGING WORSENS THE EFFECTS OF MILD MTHFR DEFICIENCY ON p-Tau
IN SUSCEPTIBLE REGIONS
Notably, Mthfr polymorphisms have been identified as a risk
factor for AD, an age-related disorder (Wang et al., 2005, 2008;
Kageyama et al., 2008; Hua et al., 2011; Coppede et al., 2012;
Mansouri et al., 2013). Thus, we next addressed the hypothesis
that normal aging could aggravate the detrimental effects of
MTHFR deficiency on LCMT1, PP2A methylation and p-Tau. To
that end, we comparatively analyzed regional brain homogenates
from 22-month-old wt and het Mthfr mice fed an amino acid
defined diet with normal folate content (normal folate diet,
NF). Null Mthfr−/− mice could not be used in these studies,
since mice with severe MTHFR deficiency die prematurely as a
result of atherosclerosis and other complications (Chen et al.,
2001; Lawrance et al., 2011). Similar to the effects of MTHFR
deficiency in young Mthfr+/− mice (Figure 2), plasma tHcy
levels were increased by an average of ∼1.6-fold in old Mthfr+/−
mice, relative to wt controls (Figure 5A). Besides promoting
hyperhomocysteinemia, MTHFR deficiency leads to altered folate
distribution and reduction in plasma and brain 5-MTHF levels
(Chen et al., 2001; Ghandour et al., 2004). Accordingly, plasma 5-
MTHF levels were significantly decreased in old het vs. wt animals
(Figure 5B). These metabolic changes were associated with a
marked decrease of PP2Ac methylation in all the brain regions
examined from het mice (Figure 6A), reinforcing the hypothesis
that alterations in plasma tHcy and 5-MTHF levels can lead to
inhibition of SAM-dependent, LCMT1-mediated PP2A methyla-
tion in the brain. Relative to controls, there was also a small but
statistically significant down regulation of LCMT1 protein expres-
sion levels in all brain regions examined from old het MTHFR+/−
mice (Figures 6B,C); again, the loss of LCMT1 and methylated
PP2Ac was more pronounced in the hippocampus. As observed in
young Mthfr+/− het mice, reduced PP2A/Bα levels (Figures 7A,B)
correlated with enhanced p-Tau phosphorylation at the PHF-
1 epitope (Figures 7C,D) in the hippocampus, cerebellum and
cortex from old het Mthfr+/− mice.
FIGURE 5 | Plasma metabolite levels in old mice models of mild
MTHFR deficiency. Plasma tHcy (A) and 5-MTHF (B) levels were
determined in 22-month-old wt mthfr+/+ and het mthfr+/− mice that had
been fed for 6 months an amino acid defined diet with either a normal
folate (NF) or a low folate (LF) content. Values represent mean ± SD for 10
mice per group; * p < 0.05, het vs. wt in the same diet group; # p < 0.05,
LF vs. NF in the same genotype.
Overall, our data indicate that the MTHFR genotype very
similarly influenced LCMT1, methylated PP2Ac and PP2A/Bα
protein expression levels in regional brain homogenates from
young and old het MTHFR+/−mice, relative to their age-matched
wt littermates. However, aging appeared to slightly worsen the
effects of mild MTHFR deficiency on p-Tau, which selectively
accumulated in the hippocampus, cerebellum and cortex of old,
but not young het Mthfr+/− mice.
MILD MTHFR DEFICIENCY WORSENS THE EFFECTS OF FOLATE
DEFICIENCY ON LCMT1 AND PP2A IN SUSCEPTIBLE BRAIN REGIONS
Interestingly, the relatively mild functional clinical consequences
of Mthfr 677C→T polymorphisms are aggravated by deficien-
cies in dietary folate intake (Botto and Yang, 2000; Rozen,
2000; Schwahn and Rozen, 2001; Leclerc and Rozen, 2007). By
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FIGURE 6 | Brain region-specific effects of folate and mild MTHFR
deficiencies on PP2A methylation and LCMT1 expression levels.
22-month-old wt mthfr+/+ and het mthfr+/− mice were fed for 6 months
either a NF diet (Black bars, wt mice; gray bars, het mice) or a LF diet
(hatched black bars, wt mice; hatched light gray bars, het mice). Relative
methylated PP2Ac (A) and LCMT1 (B,C) protein expression levels were
determined after quantitative Western blotting. Values represent
mean ± SD for 9 mice per group; * p < 0.05, het vs. wt in the same diet
group; # p < 0.05, LF vs. NF in the same genotype. Representative LCMT1
blots for two regions are shown in (B).
functionally affecting the activity of methionine synthase, a key
enzyme of the folate and methylation cycle (Figure 1), folate
deficiency restricts Hcy metabolism, resulting in elevation of
plasma tHcy levels (Fowler, 2005). Of particular significance, low
folate status and elevated tHcy levels are independent risks factors
for AD (Zhuo et al., 2011; Morris, 2012), and patients with AD
have lower plasma folate levels (Lopes da Silva et al., 2014). Based
FIGURE 7 | Brain region-specific effects of folate and mild MTHFR
deficiencies on PP2A/Bα and p-Tau expression levels. Regional brain
homogenates from the same mice described in Figure 6 were
comparatively analyzed by quantitative Western blotting for relative protein
expression levels of PP2A/Bα (A,B) and Tau phosphorylated at the PHF-1
epitope (C–D). Bar shading and symbols as in Figure 6. Representative
blots for two regions are shown in (A) and (C).
on these critical observations, we examined whether dietary folate
deficiency can affect the levels of LCMT1, PP2A and p-Tau levels
in old mice, either by itself or in synergy with mild MTHFR
deficiency. Low folate status was induced by feeding∼16-month-
old mice an amino acid defined diet with reduced folate content
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(low folate diet, LF) for 6 months. As predicted, plasma tHcy
levels were significantly increased (Figure 5A), and 5-MTHF
levels were dramatically reduced (Figure 5B) in 22-month-old wt
mice fed the LF diet, compared to age-matched control animals
receiving the NF diet. Mild MTHFR deficiency in het Mthfr+/−
mice aggravated the hyperhomocysteinenia induced by the LF diet
(Figure 5A, het vs. wt mice). However, it failed to further affect
plasma 5-MTHF levels (Figure 5B, het vs. wt mice), probably
because those were already maximally decreased in response to
the prolonged dietary folate deficiency. Comparative Western blot
analyses of tissue homogenates from wt mice fed a NF or LF diets
showed that folate deficiency alone led to a significant down regu-
lation of methylated PP2Ac (Figure 6A), LCMT1 (Figures 6B,C)
and PP2A/Bα (Figures 7A,B), and concomitant accumulation
of p-Tau (Figures 7C,D) in all brain regions examined. Again,
the LF diet-induced enhancement of Tau phosphorylation was
especially prominent in the hippocampus, cerebellum and cortex.
Comparative analysis of het mice showed that mild MTHFR
deficiency further exacerbated the effects of folate deficiency
on PP2Ac methylation (Figure 6A), LCMT1 (Figure 6C) and
PP2A/Bα expression levels (Figure 7B) in a brain region-specific
manner. Despite inducing a greater reduction in the amounts
of PP2A/Bα levels in susceptible regions (hippocampus, cerebel-
lum), there was no apparent effect of the Mthfr+/− genotype on
p-Tau levels in mice fed the LF diet (Figures 7C,D). This suggests
that endogenous Tau phosphorylation had already peaked to
its maximum level in response to the dietary folate deficiency
alone.
DISCUSSION
SEVERE MTHFR DEFICIENCY AFFECTS LCMT1-DEPENDENT PP2A
METHYLATION, PP2A/Bα AND p-Tau EXPRESSION LEVELS IN THE
HIPPOCAMPUS, CEREBELLUM AND CORTEX
It is well established that disturbances in folate metabolism exert
a detrimental effect on the brain by affecting the supply of methyl
groups that are critical for normal homeostasis; indeed, individu-
als with severe MTHFR deficiency have a variety of neurological
problems and decreased mental abilities (Watkins and Rosenblatt,
2012). Null Mthfr−/−mice have been found to have abnormalities
in the size and/or structure of the cerebellum, cortex and hip-
pocampus, and to exhibit memory impairment and other behav-
ioral anomalies reminiscent of those encountered in patients with
severe MTHFR deficiency (Chen et al., 2001, 2005; Jadavji et al.,
2012). Here, using Mthfr−/− knockout mice, we show for the
first time that severe MTHFR deficiency can impair LCMT1-
dependent PP2A methylation. PP2A is a family of abundant brain
Ser/Thr phosphatases that collectively participate in nearly all
aspects of neuronal homeostasis. Of particular interest, biogenesis
of major PP2A/Bα isoforms that are primary brain enzymes that
dephosphorylate Tau, is critically influenced by LCMT1-mediated
PP2Ac methylation (Lee and Pallas, 2007; Sontag et al., 2008).
Decreased PP2A methylation and PP2A/Bα expression levels cor-
relate with enhanced tau phosphorylation in several mouse mod-
els of altered one-carbon metabolism Reviewed in Sontag and
Sontag (2014) and in diabetic mice (Papon et al., 2013). Notably,
altered phosphorylation of Tau is a central pathological event
believed to initiate Tau aggregation and dysfunction, ultimately
resulting in neurodegeneration and cognitive decline in AD and
other tauopathies. There is also substantial evidence that the
accumulation of p-Tau is a central mediator of amyloid-β toxicity
and synaptic deficits in AD (Liao et al., 2014). Significantly, we
demonstrate in vivo that severe MTHFR deficiency is associated
with down regulation of LCMT1 and PP2A/Bα, and concomi-
tant enhancement of Tau phosphorylated at the AD-like PHF-
1 epitope in the hippocampus and cerebellum, and to a lesser
extent in the cortex. Alterations in p-Tau in the hippocampus, a
region critically involved in spatial learning and memory, could
contribute to some of the cognitive deficits previously reported
in Mthfr−/− mice (Chen et al., 2001, 2005; Jadavji et al., 2012).
Because of the prominent position of PP2A in neuronal signal-
ing, deregulation of LCMT1-dependent PP2A methylation also
provides a novel insight into the mechanisms by which MTHFR
deficiency can negatively impact neuronal function in specific
susceptible regions (hippocampus, cerebellum, cortex) identified
in earlier Mthfr−/− mouse studies (Chen et al., 2001, 2005;
Jadavji et al., 2012). Interestingly, the hippocampus and cortex are
especially vulnerable to AD-related pathological p-Tau changes,
while the cerebellum is traditionally spared in this neurodegen-
erative disorder. Accordingly, using a large series of neuropatho-
logically confirmed autopsy cases of AD, we have shown that
down regulation of LCMT1, PP2Ac methylation (Sontag et al.,
2004a) and PP2A/Bα (Sontag et al., 2004b) occurs in AD-affected
cortical and hippocampal regions, where it correlates with the
accumulation of p-Tau. In contrast, we have not observed a
concomitant loss of these enzymes in the AD cerebellum, a region
wherein neuronal p-Tau lesions do not accumulate. Yet, down
regulation of PP2A methylation in wt mice increases cerebellar
p-Tau levels (Bottiglieri et al., 2012) and excitoxicity influences
PP2A-dependent tau phosphorylation in cerebellar granule cells
(Kuszczyk et al., 2009), further demonstrating the tau regulatory
function of PP2A in the cerebellum. While MTHFR deficiency-
induced cerebellar p-Tau changes may not directly relate to the
neurodegenerative process in AD, it is worth mentioning that low
concentrations of 5-MTHF in the cerebrospinal fluid have been
linked to cerebellar atrophy and neurological disorders in children
(Grapp et al., 2012).
We noticed that severe MTHFR deficiency affected PP2Ac
methylation in all brain regions, albeit with distinct intensity. Yet,
this did not automatically translate into the loss of PP2A/Bα,
which better correlated with the down regulation of LCMT1.
These data suggest the existence of additional brain-region spe-
cific regulation of these enzymes- for instance transcription,
synthesis, degradation- and/or compensatory mechanisms that
will need to be investigated in future studies. Alternatively, a
certain threshold loss of LCMT1 activity/expression and PP2Ac
methylation may need to be reached to observe an effect on
PP2A/Bα expression levels. Inherent limitations of quantitative
Western blotting may preclude the measurement of subtle changes
in the expression of these PP2A isoforms. Moreover, while both
down regulation of SAM-dependent LCMT1 activity and LCMT1
protein expression levels can inhibit PP2Ac methylation (Sontag
et al., 2008), alterations in the protein amounts of PME-1, the
dedicated PP2A methylesterase, could also contribute to the
observed accumulation of demethylated PP2Ac. For instance,
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previous studies have shown that incubation of primary neurons
with folate antagonists can induce an up-regulation of PME-
1 that correlates with an increase of endogenous demethylated
PP2A (Yoon et al., 2007). We have also observed changes in
PME-1 levels in wt mice fed for 2 months on a folate deficient
diet (Sontag et al., 2008). Unfortunately, due to shortage of
tissue material, we were unable in the present study to measure
expression levels of PME-1 in corresponding brain regions of our
mthfr knockouts.
MILD MTHFR DEFICIENCY AFFECTS LCMT1, PP2A METHYLATION,
PP2A/Bα AND p-Tau (PHF-1) IN A BRAIN-REGION SPECIFIC MANNER
There is substantial evidence that common single human Mthfr
polymorphisms that have a frequency of up to 50% in certain
populations (Zappacosta et al., 2014), modify the risk for numer-
ous diseases (Nazki et al., 2014). Of particular interest here,
Mthfr polymorphisms that result in mild MTHFR deficiency have
been identified as a risk factor for AD in selected populations
(Wang et al., 2005, 2008; Kageyama et al., 2008; Hua et al., 2011;
Coppede et al., 2012; Mansouri et al., 2013). Moreover, epigenetic
mechanisms involving Mthfr and altered methylation homeostasis
may predispose to development of late-onset AD (Wang et al.,
2008). Interestingly, we found that mild MTHFR deficiency was
able to induce a variable down regulation of PP2Ac methylation
in all brain regions examined, and the intensity of these effects
was comparable in young or old Mthfr+/− mice, relative to age-
matched wt littermates. A similar small loss in LCMT1 protein
levels was observed in the hippocampal, cerebellar and cortical
regions of young and old Mthfr knockouts. In 22-month-old
Mthfr+/− mice, reduced expression of PP2A/Bα again correlated
with increased levels of p-Tau, in agreement with the role of
this isoform as a primary Tau phosphatase. In contrast, we were
unable to detect an increase in Tau phosphorylation at the PHF-1
epitope in young Mthfr+/− animals, relative to controls, despite
the small decrease in PP2A/Bα levels observed in the hippocam-
pus and cerebellum. It is possible that Tau protein Ser/Thr kinases
could compensate for the small regional decrease of PP2A/Bα and
maintain a steady state of Tau phosphorylation in the brain of 5-
week-old mice. Those compensatory mechanisms might become
compromised with aging, or the small loss of PP2A/Bα could
have a compounding effect with time, resulting in the increased
tau phosphorylation observed in older Mthfr+/− mice. Another
alternative is that Tau could become phosphorylated at other
epitopes not studied here, due to the lack of sufficient amounts
of regional brain tissue. The PHF-1 is considered a late phospho-
Tau epitope in AD, and PP2A methylation regulates many other
“earlier” Tau phosphorylation sites (Sontag et al., 2007) that could
be potentially sensitive to the effects of mild MTHFR deficiency
in young animals. However, we were unable to detect increased
phosphorylation of Tau at pSer422 in cortical homogenates from
young het Mthfr mice (data not shown).
INTERACTIONS BETWEEN THEMthfr GENOTYPE AND DIETARY FOLATE
DEFICIENCY DIFFERENTIALLY AFFECT LCMT1, PP2A AND p-Tau IN
DISTINCT BRAIN REGIONS
We have previously reported that LCMT1, PP2Ac methylation
and PP2A/Bα become down regulated, and Tau phosphorylation
is increased in the cerebellum and cortex, and to a lesser extent
in the midbrain and striatum of 4-week-old wt mice fed for 2
months a LF diet (Sontag et al., 2008). Here, we found sim-
ilar results in 22-month-old wt mice that had been fed for 6
months a LF diet (Figures 6, 7), except that the prolonged
diet induced more intense effects. We also show here that the
hippocampus is especially sensitive to the effects of dietary folate
deficiency, which resulted in nearly 30% loss of LCMT1, 50%
loss of methylated PP2Ac, and concomitant doubling of p-Tau
(PHF-1) levels in wt mice fed the LF diet, relative to control
animals fed the NF diet. Whether down regulation of LCMT1
results either from prolonged inhibition of its methyltransferase
activity -due to hyperhomocysteinemia and decreased cellular
methylation potential- or other regulatory mechanisms remains
to be defined. Of note, folate deficiency aggravated the nega-
tive effects of mild MTHFR deficiency on LCMT1 and PP2A
methylation in a region-specific manner. Dietary folate defi-
ciency also synergized with the Mthfr+/− genotype to further
exacerbate the loss of PP2A/Bα in the hippocampus and cere-
bellum. However, this did not lead to a further enhancement
of p-Tau levels in these regions, probably because p-Tau was
already maximally increased in response to the LF diet alone.
Altogether, these findings suggest brain-region specific responses
to the effects of both dietary folate and MTHFR deficiencies.
Further studies will be required to determine whether those are
related to either differential expression patterns of all proteins
involved, or compensatory mechanisms. Nevertheless, our find-
ings clearly establish deregulated LCMT1 and PP2A as novel
brain intermediates of the detrimental effects of MTHFR defi-
ciency. Our results also unveil for the first time a link between
MTHFR deficiency and deregulation of Tau phosphorylation,
which could explain -at least in part- why epidemiological stud-
ies have identified Mthfr polymorphisms as risk factors for
AD. Our experimental data also reinforce the notion that this
risk may be modulated by folate intake. Significantly, the age-
related decline of brain 5-MTHF levels (Bottiglieri et al., 2000)
is associated with increased levels of p-Tau and cognitive decline
(Herrmann and Obeid, 2007). Besides promoting tau phospho-
rylation, down regulation of LCMT1 and PP2A methylation can
also affect amyloid protein precursor phosphorylation and pro-
cessing (Sontag et al., 2007). Whether MTHFR polymorphisms
also influence AD risk by altering amyloidogenesis remains to be
investigated.
Due to the critical and ubiquitous cellular functions of
PP2A enzymes, MTHFR-mediated PP2A dysfunction is likely to
have functional consequences reaching far beyond the scope of
Tau deregulation and AD. For instance, Mthfr polymorphisms
influence the risk for many other neurological, vascular and
developmental disorders that affect the CNS, as well as the
pharmacodynamics of antifolates and effectiveness and toxicity of
many therapeutic drugs (Schwahn and Rozen, 2001).
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